Table 5.
Comparison among chemoradiotherapy studies, using nedaplatin/5-FU for esophageal cancer
| A. Daily low-dose nedaplatin and 5-FU regimens | ||||||||
|---|---|---|---|---|---|---|---|---|
| Author | No. |
Radiation (Gy) |
Total dose (mg) Nedaplatin 5-FU |
Stage |
RR (%) |
CR (%) |
Survival rate (%) | Leucopenia (%) |
| Inaba H [37] |
10 | 60 | 200/body 10,000/body |
I--IVB | 80 | 50 | 80 (1 y) | 90 |
| Osawa S * | 33 | 50.4--66 | 200/body 10,000/body |
I--IVB | 90.9 | 60.6 | 83 (1 y) 77 (2 y) |
75.8 |
| B. Intermittent standard-dose nedaplatin and 5-FU regimens | ||||||||
| Author | No. |
Radiation (Gy) |
Total dose (mg) Nedaplatin 5FU |
Stage |
RR (%) |
CR (%) |
Survival rate (%) | Leucopenia (%) |
| Kato H [38] |
22 | 60--66 | 160/m2 5,000/m2 |
I--IV | 77 | 9 | 30.7 (1 y) 10.2 (2 y) |
15.4 |
| 17 | 40 | 80/m2 25,000/m2 |
pre-S II--IV |
70.6 | 28.6 | 48.2 (1 y) 12.1 (2 y) |
||
| Yamanaka H [39] |
17 | 40 | 200/body 14,000/body |
I--IVB | 76.5 | 11.8 | 52.9 (1 y) | 17.6 |
| Nemoto K [40] |
17 | 60--70 | 200/body 15,000/body |
I--IVA | 94.1 | 41.2 | 59 (1 y) 39 (2 y) |
25 |
| 7 | 60--70 | 200/body 15,000/body |
post-S recur |
100 | 0 | 69 (1 y) 69 (2 y) |
||
| Ishikura S [14] |
26 | 60 | 180/m2 8,000/m2 |
III--IVB | --- | 12 | 50 (1 y) 31 (2 y) |
35 |
| Sato Y [12] |
26 | 60 | 100/m2 4,000/m2 |
I--IVA | 88.5 | 42.3 | 65.1 (1 y) 37.2 (3 y) |
40 |
| Kodaira T [13] |
40 | 60 | 360/m2 10,500/m2 |
III--IV | 76 | 48 | 58.9 (1 y) 45.9 (2 y) |
80 |
| Yamashita H [41] |
12 | 50.4 | 160/m2 6,400/m2 |
II--IVB | 82 | 73 | 40 (1 y) 13 (2 y) |
50 |
| Jingu K [42] |
30 | 60 | 140/m2 5,000/m2 |
post-S recur |
73.3 | 13.3 | 60.6 (1 y) 56.3 (3 y) |
30 |
*, present study; RR, response rate; CR, complete response; pre-S, pre-surgical; post-S recur, post-surgical recurrence; 1 y, 1-year; 2 y, 2-year